|
|
MCPH1 |
microcephalin 1 |
- Condensation of Prophase Chromosomes
|
|
- Primary microcephaly (MCPH)
|
|
|
MECP2 |
methyl-CpG binding protein 2 |
|
|
- Non-syndromic X-linked mental retardation
- Rett syndrome
- Prader-Willi and Angelman syndromes, including: Angelman syndrome (AS); Prader-Willi syndrome (PWS)
|
|
|
MESD |
mesoderm development LRP chaperone |
|
|
|
|
|
MIF4GD |
MIF4G domain containing |
|
|
|
|
|
MRPL53 |
mitochondrial ribosomal protein L53 |
- Mitochondrial translation initiation
- Mitochondrial translation elongation
- Mitochondrial translation elongation
- Mitochondrial translation termination
|
|
|
|
|
MXI1 |
MAX interactor 1, dimerization protein |
|
|
|
|
|
MYC |
MYC proto-oncogene, bHLH transcription factor |
- Transcription of E2F targets under negative control by DREAM complex
- NOTCH1 Intracellular Domain Regulates Transcription
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- MAPK6/MAPK4 signaling
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- RUNX3 regulates WNT signaling
- Estrogen-dependent gene expression
- Transcriptional regulation of granulopoiesis
|
- Acetylsalicylic acid
- Nadroparin
|
- Choriocarcinoma
- Penile cancer
- Burkitt lymphoma
- Oral cancer
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
- Multiple myeloma
- Small cell lung cancer
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
- Osteosarcoma
- Kaposi's sarcoma
- Laryngeal cancer
- Breast cancer
- Ovarian cancer
|
|
|
NCK2 |
NCK adaptor protein 2 |
- Downstream signal transduction
- Nephrin family interactions
- Ephrin signaling
- Activation of RAC1
- VEGFA-VEGFR2 Pathway
- Regulation of cortical dendrite branching
|
|
|
|
|
NONO |
non-POU domain containing octamer binding |
|
|
|
|
|
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
- Nuclear Receptor transcription pathway
|
|
|
|
|
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Circadian Clock
- SUMOylation of intracellular receptors
- PTK6 Expression
- Regulation of RUNX2 expression and activity
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Potential therapeutics for SARS
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol acetate
- Levonorgestrel
- Beclomethasone dipropionate
- Progesterone
- Spironolactone
- Betamethasone
- Desoximetasone
- Fluticasone propionate
- Fluocinolone acetonide
- Ulobetasol
- Triamcinolone
- Prednisone
- Flumethasone
- Fludrocortisone
- Norethisterone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol etabonate
- Rimexolone
- Methylprednisolone
- Clobetasol propionate
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Drospirenone
- Ciclesonide
- Hexane-1,6-Diol
- Aldosterone
- ORG-34517
- Difluprednate
- Ulipristal
- Fluticasone furoate
- Tixocortol
- Difluocortolone
- Gestrinone
- Deflazacort
- Onapristone
- Cortivazol
- Clobetasone
- Fluticasone
- Mometasone furoate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Segesterone acetate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
- Prednisolone acetate
|
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|
|
|
OSGIN1 |
oxidative stress induced growth inhibitor 1 |
|
|
|
|
|
OTX2 |
orthodenticle homeobox 2 |
|
|
- Anophthalmia and microphthalmia (A/M)
- Septo-optic dysplasia
|
|
|
PDPK1 |
3-phosphoinositide dependent protein kinase 1 |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Activation of AKT2
- Downstream TCR signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated NF-kB activation
- Integrin signaling
- CD28 dependent PI3K/Akt signaling
- G beta:gamma signalling through PI3Kgamma
- RSK activation
- VEGFR2 mediated vascular permeability
- VEGFR2 mediated cell proliferation
- CLEC7A (Dectin-1) signaling
- RHO GTPases activate PKNs
- Constitutive Signaling by AKT1 E17K in Cancer
- Regulation of TP53 Degradation
- Estrogen-stimulated signaling through PRKCZ
- Estrogen-stimulated signaling through PRKCZ
|
- Celecoxib
- Inositol 1,3,4,5-Tetrakisphosphate
- 7-Hydroxystaurosporine
- Bisindolylmaleimide VIII
- Staurosporine
- Bisindolylmaleimide I
- Dexfosfoserine
- 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine
- 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE
- 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA
- 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine
- 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione
- 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE
- Fostamatinib
|
|
|
|
PICK1 |
protein interacting with PRKCA 1 |
- Cell surface interactions at the vascular wall
- Trafficking of GluR2-containing AMPA receptors
|
|
|
|
|
PPP1CC |
protein phosphatase 1 catalytic subunit gamma |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Triglyceride catabolism
- Downregulation of TGF-beta receptor signaling
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- Circadian Clock
- RHO GTPases Activate Formins
- RAF activation
- Mitotic Prometaphase
- EML4 and NUDC in mitotic spindle formation
- Signaling by MRAS-complex mutants
|
- 9,10-Deepithio-9,10-Didehydroacanthifolicin
- Calyculin A
- Motuporin
|
|
|
|
PPP1R15A |
protein phosphatase 1 regulatory subunit 15A |
- Downregulation of TGF-beta receptor signaling
- Response of EIF2AK1 (HRI) to heme deficiency
|
|
|
|
|
PRKAB2 |
protein kinase AMP-activated non-catalytic subunit beta 2 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Macroautophagy
- AMPK inhibits chREBP transcriptional activation activity
- AMPK inhibits chREBP transcriptional activation activity
- Carnitine metabolism
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Energy dependent regulation of mTOR by LKB1-AMPK
- TP53 Regulates Metabolic Genes
- Regulation of TP53 Activity through Phosphorylation
- Lipophagy
- Activation of AMPK downstream of NMDARs
|
- Adenosine phosphate
- Acetylsalicylic acid
- Fostamatinib
|
|
|
|
PRMT5 |
protein arginine methyltransferase 5 |
- snRNP Assembly
- RMTs methylate histone arginines
- Regulation of TP53 Activity through Methylation
|
|
|
|
|
PSMB1 |
proteasome 20S subunit beta 1 |
- Activation of NF-kappaB in B cells
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- ER-Phagosome pathway
- Cross-presentation of soluble exogenous antigens (endosomes)
- Autodegradation of Cdh1 by Cdh1:APC/C
- SCF-beta-TrCP mediated degradation of Emi1
- APC/C:Cdc20 mediated degradation of Securin
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Cdc20:Phospho-APC/C mediated degradation of Cyclin A
- Vpu mediated degradation of CD4
- Vif-mediated degradation of APOBEC3G
- SCF(Skp2)-mediated degradation of p27/p21
- Degradation of beta-catenin by the destruction complex
- Downstream TCR signaling
- Regulation of activated PAK-2p34 by proteasome mediated degradation
- Separation of Sister Chromatids
- FCERI mediated NF-kB activation
- Autodegradation of the E3 ubiquitin ligase COP1
- Regulation of ornithine decarboxylase (ODC)
- ABC-family proteins mediated transport
- AUF1 (hnRNP D0) binds and destabilizes mRNA
- Asymmetric localization of PCP proteins
- Degradation of AXIN
- Degradation of DVL
- Hedgehog ligand biogenesis
- Hh mutants are degraded by ERAD
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- Degradation of GLI1 by the proteasome
- Degradation of GLI2 by the proteasome
- GLI3 is processed to GLI3R by the proteasome
- Hedgehog 'on' state
- Regulation of RAS by GAPs
- TNFR2 non-canonical NF-kB pathway
- NIK-->noncanonical NF-kB signaling
- Defective CFTR causes cystic fibrosis
- MAPK6/MAPK4 signaling
- UCH proteinases
- Ub-specific processing proteases
- Neutrophil degranulation
- CDT1 association with the CDC6:ORC:origin complex
- Orc1 removal from chromatin
- CDK-mediated phosphorylation and removal of Cdc6
- G2/M Checkpoints
- Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
- Ubiquitin-dependent degradation of Cyclin D
- The role of GTSE1 in G2/M progression after G2 checkpoint
- FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Regulation of RUNX3 expression and activity
- Regulation of PTEN stability and activity
- Neddylation
- Regulation of expression of SLITs and ROBOs
- Interleukin-1 signaling
- Negative regulation of NOTCH4 signaling
- Antigen processing: Ubiquitination & Proteasome degradation
|
- Bortezomib
- (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE
- Carfilzomib
|
|